



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Manali Mukherjee  
✉ mukherj@mcmaster.ca

†These authors have contributed equally to  
this work

RECEIVED 09 January 2025  
ACCEPTED 10 January 2025  
PUBLISHED 21 January 2025

CITATION  
Thawanaphong S, Nair A, Volfson E, Nair P  
and Mukherjee M (2025) Corrigendum: IL-18  
biology in severe asthma.  
*Front. Med.* 12:1558229.  
doi: 10.3389/fmed.2025.1558229

COPYRIGHT  
© 2025 Thawanaphong, Nair, Volfson, Nair  
and Mukherjee. This is an open-access article  
distributed under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#). The  
use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: IL-18 biology in severe asthma

Sarita Thawanaphong<sup>1,2,3†</sup>, Aswathi Nair<sup>1,2†</sup>, Emily Volfson<sup>1,2†</sup>,  
Parameswaran Nair<sup>1,2</sup> and Manali Mukherjee<sup>1,2\*</sup>

<sup>1</sup>Department of Medicine, McMaster University, Hamilton, ON, Canada, <sup>2</sup>Research Institute of St. Joe's Hamilton, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, <sup>3</sup>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

## KEYWORDS

IL-18, autoimmunity, asthma, inflammasome, eosinophilia

## A Corrigendum on IL-18 biology in severe asthma

by Thawanaphong, S., Nair, A., Volfson, E., Nair, P., and Mukherjee, M. (2024). *Front. Med.* 11:1486780. doi: 10.3389/fmed.2024.1486780

In the published article, there was an error in **Table 3**. In Row 2, Column 1, the manufacturer information for APB-R3 is incorrectly listed as “Sigma-Aldrich.” The corrected Table 3, Row 2, Column 1 appear below.

### APB-R3 (AprilBio Co., Ltd.)

In Row 2, Column 4, the status of the study in Healthy Subjects was previously noted as “Ongoing Phase I study (NCT05715736).” The corrected **Table 3**, Row 2, Column 4, the fourth bullet appear below.

### Healthy Subjects: Completed Phase I study (NCT05715736).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.